Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms
Authors:
Open Access
- 10 April 2013
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 4 (4) , 622-635
Abstract
Constitutively activated signaling molecules are often the primary drivers of malignancy, and are favored targets for therapeutic intervention. However, the effectiveness of targeted inhibition of cell signaling can be blunted by compensatory signaling which generates adaptive resistance mechanisms and reduces therapeutic responses. Therefore, it is important to identify and target these compensatory pathways with combinations of targeted agents to achieve durable clinical benefit. In this report, we demonstrate the use of high-throughput combinatorial drug screening as a discovery tool to identify compensatory pathways that generate resistance to the cytotoxic effects of targeted therapy. We screened 420 drug combinations in 14 different cell lines representing three cancer lineages, and assessed the ability of each combination to cause synergistic cytotoxicity. Drug substitution studies were used to validate the functionally important drug targets. Of the 84 combinations that caused robust synergy in multiple cell lines, none were synergistic in more than half of the lines tested, and we observed no pattern of lineage specificity in the observed synergies. This reflects the plasticity of cell signaling networks, even among cell lines of the same tissue of origin. Mechanistic analysis of one novel synergistic combination identified in the screen, the multi-kinase inhibitor Ro31-8220 and lapatinib, demonstrated compensatory crosstalk between the p70S6 kinase and EGF receptor pathways. In addition, we identified BAD as a node of convergence between these two pathways that may be playing a role in the enhanced apoptosis observed upon combination treatment.Keywords
This publication has 32 references indexed in Scilit:
- Negative Feedback and Adaptive Resistance to the Targeted Therapy of CancerCancer Discovery, 2012
- Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate CancerMolecular Cancer Therapeutics, 2011
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerOncogene, 2011
- CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 PhosphorylationMolecular Endocrinology, 2010
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyMolecular Cancer, 2010
- Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokinesJournal of Inflammation, 2009
- Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional CapacityPLOS ONE, 2008
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000
- The Hallmarks of CancerCell, 2000